Developing antibodies to fight insect-borne viruses
Official title: Project 5: mAb Development Flaviviruses and Alphaviruses
Funded at Washington University · NIH-10863006 · Data updated 2026-11-12
This study is working on developing new treatments using special antibodies to help people who are suffering from serious illnesses caused by viruses like dengue and chikungunya, with the hope of offering better protection and options for recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 12, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $5,594,501 |
| NIH project number | 1U19AI181960-01 |
| Project ID | NIH-10863006 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have been infected with or are at risk of infection from flaviviruses or alphaviruses.
✕Less likely to help
Patients who are not affected by flavivirus or alphavirus infections are unlikely to benefit from this research.
What this research studies
This research focuses on creating and validating human monoclonal antibodies (mAbs) to combat severe diseases caused by flaviviruses and alphaviruses, such as dengue and chikungunya. The project employs various antibody discovery techniques to identify the most effective mAbs and explores how to combine them for enhanced protection against these viruses. Additionally, it aims to develop computational methods to improve the effectiveness of these antibodies and create treatments that mimic vaccine responses. The ultimate goal is to provide new therapeutic options for patients suffering from these viral infections.
Why it matters
Potential benefit: If successful, this research could lead to new antibody-based treatments that significantly reduce the severity of diseases caused by flaviviruses and alphaviruses.
How similar studies have gone: Previous research has shown promise in developing antibody treatments for similar viral infections, indicating a potential for success in this approach.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Crowe, James E — Washington University
- Study coordinator: Crowe, James E
Related research
Other NIH-funded projects on the same topics.
-
Using MRI to measure brain oxygen levels as an early sign of small vessel disease in the brain
This study is looking at how measuring oxygen levels in the brain with MRI can help spot early signs of small vessel disease, which is linked to memory problems and dementia, especially Alzheimer's, so if you're at risk due to age or high blood pressure, you might be able to participate in MRI scans to learn more about
-
Advanced Methods & Modeling for Better Patient Care
A funding opportunity focused on developing new modeling methods to improve health care for patients through better data use and analytics.
-
Advanced methods and modeling for health research at Washington University
A health research grant at Washington University funds new modeling methods to support future patient-focused studies.
-
Center for Research in Emerging Infectious Diseases: Epidemiology, Surveillance and Pathogenesis
A NIH program will study and monitor emerging viruses from the Midwest U.S. and three Asian sites to understand how they spread and affect people.
-
How Poverty and the Environment Affect Heart Disease in Haiti and Beyond
This grant studies how poverty-related factors like food insecurity, stress, and pollution contribute to heart disease and aims to follow a large group of adults to better understand and prevent the disease.
-
Wearable tech to track blood loss during childbirth
A wearable device monitors cardiovascular signals to detect postpartum hemorrhage early so clinicians can act quickly to protect mothers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.